SEC Form 4 · accession 0001193125-26-294863
Cullinan Therapeutics, Inc. · CGEM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mary Kay Fenton
Officer — Chief Financial Officer
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 5:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001789972
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 30, 2026 | A | 1,541 | $8.60 | A | 127,921 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
- F2In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on January 2, 2026.